Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification.
Anatomical
CASCAP
Cholangiocarcinoma
Classification
Morphological
Survival
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
03 May 2021
03 May 2021
Historique:
received:
15
01
2021
accepted:
23
04
2021
entrez:
4
5
2021
pubmed:
5
5
2021
medline:
11
8
2021
Statut:
epublish
Résumé
Cholangiocarcinoma (CCA) has been categorized based on tumor location as intrahepatic (ICCA), perihilar (PCCA) or distal (DCCA), and based on the morphology of the tumor of the bile duct as mass forming (MF), periductal infiltrating (PI) or intraductal (ID). To date, there is limited evidence available regarding the survival of CCA among these different anatomical and morphological classifications. This study aimed to evaluate the survival rate and median survival time after curative surgery among CCA patients according to their anatomical and morphological classifications, and to determine the association between these classifications and survival. This study included CCA patients who underwent curative surgery from the Cholangiocarcinoma Screening and Care Program (CASCAP), Northeast Thailand. The anatomical and morphological classifications were based on pathological findings after surgery. Survival rates of CCA and median survival time since the date of CCA surgery and 95% confidence intervals (CI) were calculated. Multiple cox regression was performed to evaluate factors associated with survival which were quantified by hazard ratios (HR) and their 95% CIs. Of the 746 CCA patients, 514 had died at the completion of the study which constituted 15,643.6 person-months of data recordings. The incidence rate was 3.3 per 100 patients per month (95% CI: 3.0-3.6), with median survival time of 17.8 months (95% CI: 15.4-20.2), and 5-year survival rate of 24.6% (95% CI: 20.7-28.6). The longest median survival time was 21.8 months (95% CI: 16.3-27.3) while the highest 5-year survival rate of 34.8% (95% CI: 23.8-46.0) occurred in the DCCA group. A combination of anatomical and morphological classifications, PCCA+ID, was associated with the longest median survival time of 40.5 months (95% CI: 17.9-63.0) and the highest 5-year survival rate of 42.6% (95% CI: 25.4-58.9). The ICCA+MF combination was associated with survival (adjusted HR: 1.45; 95% CI: 1.01-2.09; P = 0.013) compared to ICCA+ID patients. Among patients receiving surgical treatment, those with PCCA+ID had the highest 5-year survival rate, which was higher than in groups classified by only anatomical characteristics. Additionally, the patients with ICCA+MF tended to have unfavorable surgical outcomes. Showed the highest survival association. Therefore, further investigations into CCA imaging should focus on patients with a combination of anatomical and morphological classifications.
Sections du résumé
BACKGROUND
BACKGROUND
Cholangiocarcinoma (CCA) has been categorized based on tumor location as intrahepatic (ICCA), perihilar (PCCA) or distal (DCCA), and based on the morphology of the tumor of the bile duct as mass forming (MF), periductal infiltrating (PI) or intraductal (ID). To date, there is limited evidence available regarding the survival of CCA among these different anatomical and morphological classifications. This study aimed to evaluate the survival rate and median survival time after curative surgery among CCA patients according to their anatomical and morphological classifications, and to determine the association between these classifications and survival.
METHODS
METHODS
This study included CCA patients who underwent curative surgery from the Cholangiocarcinoma Screening and Care Program (CASCAP), Northeast Thailand. The anatomical and morphological classifications were based on pathological findings after surgery. Survival rates of CCA and median survival time since the date of CCA surgery and 95% confidence intervals (CI) were calculated. Multiple cox regression was performed to evaluate factors associated with survival which were quantified by hazard ratios (HR) and their 95% CIs.
RESULTS
RESULTS
Of the 746 CCA patients, 514 had died at the completion of the study which constituted 15,643.6 person-months of data recordings. The incidence rate was 3.3 per 100 patients per month (95% CI: 3.0-3.6), with median survival time of 17.8 months (95% CI: 15.4-20.2), and 5-year survival rate of 24.6% (95% CI: 20.7-28.6). The longest median survival time was 21.8 months (95% CI: 16.3-27.3) while the highest 5-year survival rate of 34.8% (95% CI: 23.8-46.0) occurred in the DCCA group. A combination of anatomical and morphological classifications, PCCA+ID, was associated with the longest median survival time of 40.5 months (95% CI: 17.9-63.0) and the highest 5-year survival rate of 42.6% (95% CI: 25.4-58.9). The ICCA+MF combination was associated with survival (adjusted HR: 1.45; 95% CI: 1.01-2.09; P = 0.013) compared to ICCA+ID patients.
CONCLUSIONS
CONCLUSIONS
Among patients receiving surgical treatment, those with PCCA+ID had the highest 5-year survival rate, which was higher than in groups classified by only anatomical characteristics. Additionally, the patients with ICCA+MF tended to have unfavorable surgical outcomes. Showed the highest survival association. Therefore, further investigations into CCA imaging should focus on patients with a combination of anatomical and morphological classifications.
Identifiants
pubmed: 33941120
doi: 10.1186/s12885-021-08247-z
pii: 10.1186/s12885-021-08247-z
pmc: PMC8094526
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
497Références
Radiographics. 2009 May-Jun;29(3):683-700
pubmed: 19448110
Trop Geogr Med. 1991 Jan-Apr;43(1-2):193-8
pubmed: 1661041
Asian Pac J Cancer Prev. 2018 Mar 27;19(3):605-614
pubmed: 29579789
Ann Transl Med. 2019 Dec;7(23):744
pubmed: 32042760
Acta Oncol. 2019 Jul;58(7):1048-1055
pubmed: 30907207
Gastroenterology. 2009 Apr;136(4):1134-44
pubmed: 19245868
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
J Gastrointestin Liver Dis. 2010 Sep;19(3):285-90
pubmed: 20922193
BMC Cancer. 2015 Jun 09;15:459
pubmed: 26054405
Hepatogastroenterology. 2001 Jul-Aug;48(40):1129-33
pubmed: 11490816
J Hepatol. 2012 Apr;56(4):848-54
pubmed: 22173164
Crit Rev Oncol Hematol. 2009 Mar;69(3):259-70
pubmed: 18977670
BMC Cancer. 2016 Jun 02;16:346
pubmed: 27251649
Ann Surg Oncol. 2018 Apr;25(4):845-847
pubmed: 28752469
HPB (Oxford). 2017 Aug;19(8):735-740
pubmed: 28549744
Asian Pac J Cancer Prev. 2013;14(2):1107-10
pubmed: 23621195
HPB (Oxford). 2017 Nov;19(11):966-971
pubmed: 28754366
Surg Today. 2012 Dec;42(12):1189-94
pubmed: 22350300
Asian Pac J Cancer Prev. 2013;14(5):2963-6
pubmed: 23803062
World J Hepatol. 2010 Dec 27;2(12):419-27
pubmed: 21191517
Asian Pac J Cancer Prev. 2013;14(11):7029-32
pubmed: 24377644
Cancer Sci. 2010 Mar;101(3):579-85
pubmed: 20085587
Asian Pac J Cancer Prev. 2016;17(1):401-6
pubmed: 26838246
Nat Rev Gastroenterol Hepatol. 2011 Aug 02;8(9):512-22
pubmed: 21808282
HPB (Oxford). 2020 Jun;22(6):874-883
pubmed: 31662222
BMC Gastroenterol. 2017 Jan 5;17(1):3
pubmed: 28056836
Asian Pac J Cancer Prev. 2004 Apr-Jun;5(2):118-25
pubmed: 15244512